# Natera, Inc. clinical trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Natera, Inc. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Natera, Inc.: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/natera-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 13, 2026 | NCT07763197 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) | Natera, Inc. | Observational | Recruiting | Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763197) |
| August 6, 2026 | NCT07750886 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) | Natera, Inc. | Observational | Recruiting | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750886) |
| July 22, 2026 | NCT07718633 | Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) | Natera, Inc. | Not applicable | Not yet recruiting | Kidney Transplant, Immunosuppresion | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718633) |
| July 8, 2026 | NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI)... | Natera, Inc. | Not applicable | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma)... | 920 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689812) |
| May 4, 2026 | NCT07565857 | Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer | Natera, Inc. | Not applicable | Not yet recruiting | Gastric-Esophageal Cancer | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565857) |
| January 14, 2026 | NCT07339384 | Signatera Assessment in Early-Stage Endometrial Cancer | Natera, Inc. | Not applicable | Not yet recruiting | Endometrial Cancer | 1,010 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339384) |
| January 5, 2026 | NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study | Natera, Inc. | Observational | Recruiting | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer... | 9,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318051) |
| October 9, 2025 | NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Natera, Inc. | Not applicable | Recruiting | Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement) | 725 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214532) |
| July 1, 2025 | NCT07046585 | Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) | Natera, Inc. | Observational | Recruiting | Colo-rectal Cancer | 25,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046585) |
| February 5, 2025 | NCT06808880 | EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) | Natera, Inc. | Observational | Recruiting | Single Gene NIPT | 4,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06808880) |
| October 1, 2024 | NCT06620627 | Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection | Natera, Inc. | Observational | Recruiting | Colorectal Cancer Screening | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06620627) |
| May 16, 2024 | NCT06414603 | A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy | Natera, Inc. | Not applicable | Active not recruiting | Heart Transplant Failure and Rejection | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06414603) |
| May 6, 2023 | NCT05846113 | Renasight Clinical Application, Review and Evaluation (RenaCARE) Study | Natera, Inc. | Not applicable | Unknown | Kidney Diseases | 1,720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05846113) |
| April 6, 2022 | NCT05312814 | Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. | Natera, Inc. | Observational | Completed | Twin to Twin Transfusion Syndrome, Pregnancy Complications, Multiple Gestation; Maternal Care | 137 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05312814) |
| April 4, 2022 | NCT05309382 | Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation | Natera, Inc. | Observational | Completed | Heart Transplant | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05309382) |
| January 25, 2022 | NCT05205551 | Prospera Test Evaluation in Cardiac Transplant (ProTECT) | Natera, Inc. | Observational | Active not recruiting | Heart Transplant Rejection | 411 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05205551) |
| December 28, 2021 | NCT05170425 | LAMBDA 002 (Lung Registry) Study | Natera, Inc. | Observational | Active not recruiting | Lung Transplant Rejection | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05170425) |
| October 18, 2021 | NCT05081739 | Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation | Natera, Inc. | Not applicable | Withdrawn | Heart Transplant Failure and Rejection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05081739) |
| August 13, 2021 | NCT05004337 | Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies | Natera, Inc. | Observational | Completed | Vanishing Twin, Trisomy 21, Trisomy 13, Trisomy 18 | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05004337) |
| February 21, 2021 | NCT04761783 | BESPOKE Study of ctDNA Guided Immunotherapy | Natera, Inc. | Observational | Completed | Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04761783) |
| February 11, 2020 | NCT04264702 | BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer | Natera, Inc. | Observational | Unknown | Colorectal Cancer, Colon Cancer | 1,788 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04264702) |
| September 17, 2019 | NCT04091984 | The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) | Natera, Inc. | Observational | Active not recruiting | Kidney Transplant Rejection | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04091984) |
| June 13, 2019 | NCT03984747 | Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection | Natera, Inc. | Observational | Completed | Transplant Rejection, Allograft Rejection, Complications | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03984747) |
| April 2, 2018 | NCT03485651 | Natera Ovarian Cancer Detection Assay | Natera, Inc. | Observational | Terminated | Adnexal Mass | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03485651) |
| March 6, 2015 | NCT02381457 | SNP-based Microdeletion and Aneuploidy RegisTry (SMART) | Natera, Inc. | Observational | Completed | 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome... | 20,960 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02381457) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 4 | 1 |
| Not applicable | 9 |
| Observational | 26 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Recruiting | 7 |
| Active not recruiting | 4 |
| Not yet recruiting | 4 |
| Terminated | 3 |
| Withdrawn | 2 |
| Unknown | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Down Syndrome | 8 |
| Trisomy 18 Syndrome | 8 |
| Trisomy 13 Syndrome | 8 |
| Turner Syndrome | 6 |
| Sex Chromosome Aberrations | 6 |
| Colorectal Neoplasms | 5 |
| Rejection, Psychology | 3 |
| Melanoma | 3 |
| Colonic Neoplasms | 3 |
| Aneuploidy | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Breast Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Muscular Atrophy, Spinal | 1 |
| 22q11 Deletion Syndrome | 1 |
| DiGeorge Syndrome | 1 |
| Cri-du-Chat Syndrome | 1 |
| Angelman Syndrome | 1 |
| Prader-Willi Syndrome | 1 |
| Chromosome 1p36 Deletion Syndrome | 1 |
| Fetofetal Transfusion | 1 |
| Pregnancy Complications | 1 |
| Cystic Fibrosis | 1 |
| Klinefelter Syndrome | 1 |
| Kidney Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Wind energy companies in the United States](https://specstream.ai/data/businesses/wind-energy-companies/united-states)
- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
- [Community health centers in the United States](https://specstream.ai/data/businesses/community-health-centers/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
